Interpharm Holdings Return on Tangible Equity 1971-1970 | IPAH

Current and historical return on tangible equity values for Interpharm Holdings (IPAH) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Interpharm Holdings Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.000B $0.000B
Interpharm Holdings, Inc., through its wholly owned subsidiary, Interpharm, Inc., is engaged in the business of developing, manufacturing and marketing generic prescription strength and over-the-counter pharmaceuticals. The Company sells its products under its own label to the major retailers, wholesalers, managed care organizations and national distributors, and under private label to wholesalers, distributors, repackagers and other manufacturers. The Company manufactured and marketed 36 generic pharmaceutical products, which represent various oral dosage strengths for 11 products and different dosage strengths for 25 of these products.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) IL $18.357B 6.72
Dr Reddy's Laboratories (RDY) IN $11.687B 22.29
BridgeBio Pharma (BBIO) US $7.324B 0.00
Bausch Health Cos (BHC) CA $2.003B 1.45
Supernus Pharmaceuticals (SUPN) US $1.839B 17.10
Amphastar Pharmaceuticals (AMPH) US $1.164B 7.04
Taysha Gene Therapies (TSHA) US $0.529B 0.00
Personalis (PSNL) US $0.367B 0.00
Assembly Biosciences (ASMB) US $0.108B 0.00
Sol-Gel Technologies (SLGL) IL $0.020B 0.00
Evoke Pharma (EVOK) US $0.005B 0.00
Teligent (TLGT) US $0.000B 0.00